Ir al menú de navegación principal Ir al contenido principal Ir al pie de página del sitio

ANTIOXIDANT ACTIVITY OF NON-PSYCHOACTIVE CANNABIS VARIETIES FROM NORTH CAUCA, COLOMBIA

Resumen

El presente estudio tiene como objetivo dar a conocer la composición química y el posible potencial medicinal de variedades de cannabis no psicoactivo cultivadas en el departamento del Cauca. Los cannabinoides fueron identificados y cuantificados por cromatografía líquida de alta resolución acoplada a un detector ultravioleta (HPLC/UV) para el análisis de la flor, y cromatografía de gases acoplada a un espectrómetro de masas (GC-MS) para el análisis de los extractos etanólicos y contenido terpenos. Los fenoles se cuantificaron por reacción con el reactivo de Folin & Ciocalteau; para la determinación de flavonoides y antraquinonas, los extractos fueron tratados con AlCl3. Finalmente, para determinar la actividad antioxidante se utilizaron tres métodos: DPPH, ABTS y FRAP. Se pudo determinar que las variedades A y B contenían porcentajes de tetrahidrocannabinol total (THC) menores al 1% y porcentajes de cannabidiol total (CBD) entre 9-15%. En los extractos etanólicos se alcanzaron concentraciones (m/m) de CBD en las variedades A y B, del 10% y 13,7%, respectivamente. Se identificaron y cuantificaron nueve terpenos de la muestra A y siete de la muestra B, siendo el β-cariofileno el más abundante en ambos. Teniendo en cuenta que existe evidencia en la literatura de que la relación CBD/THC influye en la actividad biológica, se espera que los extractos etanólicos de las variedades A y B tengan una actividad antioxidante de moderada a baja, lo que, según algunos investigadores, puede estar asociado con el efecto neuroprotector, que puede verse favorecido por la presencia de β-cariofileno.

Palabras clave

Actividad antioxidante, Cannabinoides, Cannabis, Terpenos


Referencias

  1. Hillig KW. A systematic investigation of Cannabis: Indiana University; 2005.
  2. Bonini SA, Premoli M, Tambaro S, Kumar A, Maccarinelli G, Memo M, et al. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. Journal of ethnopharmacology. 2018;227:300-15.
  3. Charai M, Sghiouri H, Mezrhab A, Karkri M. Thermal insulation potential of non-industrial hemp (Moroccan cannabis sativa L.) fibers for green plaster-based building materials. Journal of Cleaner Production. 2021;292:126064.
  4. Gomez FP, Hu J, Clarke MA. Cannabis as a Feedstock for the Production of Chemicals, Fuels, and Materials: A Review of Relevant Studies To Date. Energy & Fuels. 2021;35(7):5538-57.
  5. Mudge EM. Chemometrics and metabolomics of Cannabis sativa L. 2019.
  6. Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. British journal of clinical pharmacology. 2018;84(11):2477-82.
  7. Mazza M. Medical Cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series. Journal of Cannabis Research. 2021;3(1):1-18.
  8. Koltai H, Namdar D. Cannabis phytomolecule'Entourage': from domestication to medical use. Trends in plant science. 2020;25(10):976-84.
  9. Gonçalves J, Rosado T, Soares S, Simão AY, Caramelo D, Luís Â, et al. Cannabis and its secondary metabolites: their use as therapeutic drugs, toxicological aspects, and analytical determination. Medicines. 2019;6(1):31.
  10. ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. Phytochemistry of Cannabis sativa L. Phytocannabinoids. 2017:1-36.
  11. Lowe H, Steele B, Bryant J, Toyang N, Ngwa W. Non-cannabinoid metabolites of Cannabis sativa L. with Therapeutic Potential. Plants. 2021;10(2):400.
  12. Solymosi K, Köfalvi A. Cannabis: a treasure trove or pandora's box? Mini reviews in medicinal chemistry. 2017;17(13):1223-91.
  13. Maurya N, Velmurugan BK. Therapeutic applications of cannabinoids. Chemico-Biological Interactions. 2018;293:77-88.
  14. Rosenberg EC, Patra PH, Whalley BJ. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy & Behavior. 2017;70:319-27.
  15. Booth JK, Bohlmann J. Terpenes in Cannabis sativa–From plant genome to humans. Plant Science. 2019;284:67-72.
  16. Yoo K-Y, Park S-Y. Terpenoids as potential anti-Alzheimer’s disease therapeutics. Molecules. 2012;17(3):3524-38.
  17. McTaggart‐Cowan H, Bentley C, Raymakers A, Metcalfe R, Hawley P, Peacock S. Understanding cancer survivors’ reasons to medicate with Cannabis: A qualitative study based on the theory of planned behavior. Cancer medicine. 2021;10(1):396-404.
  18. Holgado MA, Martín-Banderas L, Álvarez-Fuentes J, Fernández-Arévalo M. Neuroprotective effect of cannabinoids nanoplatforms in neurodegenerative diseases. Journal of Drug Delivery Science and Technology. 2017;42:84-93.
  19. Hacke ACM, Lima D, de Costa F, Deshmukh K, Li N, Chow AM, et al. Probing the antioxidant activity of Δ 9-tetrahydrocannabinol and cannabidiol in Cannabis sativa extracts. Analyst. 2019;144(16):4952-61.
  20. Namdar D, Mazuz M, Ion A, Koltai H. Variation in the compositions of cannabinoid and terpenoids in Cannabis sativa derived from inflorescence position along the stem and extraction methods. Industrial Crops and Products. 2018;113:376-82.
  21. Chye Y, Kirkham R, Lorenzetti V, McTavish E, Solowij N, Yücel M. Cannabis, Cannabinoids, and Brain Morphology: A Review of the Evidence. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2021;6(6):627-35.
  22. Minsalud. Decreto 613: Acceso seguro e informado al uso médico y científico del Cannabis. In: Colombia Gd, editor. Decreto 613. Bogotá D.C.2017. p. 1-35.
  23. Minsalud. Licencias de fabricación de derivados de Cannabis. In: Salud Md, editor. Bogotá2021.
  24. Giraldo JM, Benítez RB, Sarria-Villa RA, Arango PA, Franco JM. Determinación y comparación cualitativa de cannabinoides presentes en productos naturales comerciales del departamento del Cauca-Colombia. Revista Colombiana de Ciencias Químico-Farmacéuticas. 2019;48(3).
  25. De Backer B, Debrus B, Lebrun P, Theunis L, Dubois N, Decock L, et al. Innovative development and validation of an HPLC/DAD method for the qualitative and quantitative determination of major cannabinoids in cannabis plant material. Journal of Chromatography B. 2009;877(32):4115-24.
  26. Peschel W, Politi M. 1H NMR and HPLC/DAD for Cannabis sativa L. chemotype distinction, extract profiling and specification. Talanta. 2015;140:150-65.
  27. Citti C, Braghiroli D, Vandelli MA, Cannazza G. Pharmaceutical and biomedical analysis of cannabinoids: A critical review. Journal of pharmaceutical and biomedical analysis. 2018;147:565-79.
  28. Corni G, Brighenti V, Pellati F, Morlock GE. Effect-directed analysis of bioactive compounds in Cannabis sativa L. by high-performance thin-layer chromatography. Journal of Chromatography A. 2020;1629:461511.
  29. Berman P, Futoran K, Lewitus GM, Mukha D, Benami M, Shlomi T, et al. A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis. Scientific reports. 2018;8(1):1-15.
  30. Nemeškalová A, Hájková K, Mikulů L, Sýkora D, Kuchař M. Combination of UV and MS/MS detection for the LC analysis of cannabidiol-rich products. Talanta. 2020;219:121250.
  31. Pichini S, Malaca S, Gottardi M, Pérez-Acevedo AP, Papaseit E, Perez-Maña C, et al. UHPLC-MS/MS analysis of cannabidiol metabolites in serum and urine samples. Application to an individual treated with medical cannabis. Talanta. 2021;223:121772.
  32. Peeri H, Shalev N, Vinayaka AC, Nizar R, Kazimirsky G, Namdar D, et al. Specific Compositions of Cannabis sativa Compounds Have Cytotoxic Activity and Inhibit Motility and Colony Formation of Human Glioblastoma Cells In Vitro. Cancers. 2021;13(7):1720.
  33. Pollastro F, Minassi A, Fresu LG. Cannabis phenolics and their bioactivities. Current medicinal chemistry. 2018;25(10):1160-85.
  34. Jin D, Dai K, Xie Z, Chen J. Secondary metabolites profiled in cannabis inflorescences, leaves, stem barks, and roots for medicinal purposes. Scientific Reports. 2020;10(1):1-14.
  35. Nagy DU, Cianfaglione K, Maggi F, Sut S, Dall'Acqua S. Chemical characterization of leaves, male and female flowers from spontaneous Cannabis (Cannabis sativa L.) growing in Hungary. Chemistry & Biodiversity. 2019;16(3):e1800562.
  36. Drinić Z, Vidović S, Vladić J, Koren A, Kiprovski B, Sikora V. Effect of extraction solvent on total polyphenols content and antioxidant activity of Cannabis sativa L. Lekovite sirovine. 2018(38):17-21.
  37. Pavlovic R, Panseri S, Giupponi L, Leoni V, Citti C, Cattaneo C, et al. Phytochemical and ecological analysis of two varieties of hemp (Cannabis sativa L.) grown in a mountain environment of Italian Alps. Frontiers in Plant Science. 2019;10:1265.
  38. Pellati F, Brighenti V, Sperlea J, Marchetti L, Bertelli D, Benvenuti S. New Methods for the Comprehensive Analysis of Bioactive Compounds in Cannabis sativa L. (hemp). Molecules. 2018;23(10):2639.
  39. Izzo L, Castaldo L, Narváez A, Graziani G, Gaspari A, Rodríguez-Carrasco Y, et al. Analysis of Phenolic Compounds in Commercial Cannabis sativa L. Inflorescences Using UHPLC-Q-Orbitrap HRMS. Molecules. 2020;25(3):631.
  40. Ferrante C, Recinella L, Ronci M, Menghini L, Brunetti L, Chiavaroli A, et al. Multiple pharmacognostic characterization on hemp commercial cultivars: Focus on inflorescence water extract activity. Food and Chemical Toxicology. 2019;125:452-61.
  41. Méndez Pérez FA. Optimización de la obtención del extracto hidroalcohólico de las inflorescencias de Cannabis sativaL.“marihuana”. Ayacucho 2018. 2018.
  42. Radwan MM, Chandra S, Gul S, ElSohly MA. Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis. Molecules. 2021;26(9).
  43. Gruschow A. A Comparison of Antioxidant Potential, Total Phenolic Content, and Cannabidiol (CBD) Content of Cannabis Infused Hemp, MCT, and Olive Oils. 2020.
  44. Yadav AN, Kour D, Rana KL, Yadav N, Singh B, Chauhan VS, et al. Chapter 20 - Metabolic Engineering to Synthetic Biology of Secondary Metabolites Production. In: Gupta VK, Pandey A, editors. New and Future Developments in Microbial Biotechnology and Bioengineering. Amsterdam: Elsevier; 2019. p. 279-320.
  45. Diaz-Muñoz G, Miranda IL, Sartori SK, de Rezende DC, Diaz MAN. Chapter 11 - Anthraquinones: An Overview. In: Atta ur R, editor. Studies in Natural Products Chemistry. 58: Elsevier; 2018. p. 313-38.
  46. Montenegro I, Moreira J, Ramírez I, Dorta F, Sánchez E, Alfaro JF, et al. Chemical Composition, Antioxidant and Anticancer Activities of Leptocarpha rivularis DC Flower Extracts. Molecules. 2021;26(1):67.
  47. Shang X-F, Zhao Z-M, Li J-C, Yang G-Z, Liu Y-Q, Dai L-X, et al. Insecticidal and antifungal activities of Rheum palmatum L. anthraquinones and structurally related compounds. Industrial Crops and Products. 2019;137:508-20.
  48. Dawidowicz AL, Olszowy-Tomczyk M, Typek R. CBG, CBD, Δ9-THC, CBN, CBGA, CBDA and Δ9-THCA as antioxidant agents and their intervention abilities in antioxidant action. Fitoterapia. 2021;152:104915.
  49. Palmieri S, Pellegrini M, Ricci A, Compagnone D, Lo Sterzo C. Chemical composition and antioxidant activity of thyme, hemp and coriander extracts: A comparison study of maceration, Soxhlet, UAE and RSLDE techniques. Foods. 2020;9(9):1221.
  50. Abrams DI, Guzman M. Cannabis in cancer care. Clinical Pharmacology & Therapeutics. 2015;97(6):575-86.
  51. Avello LM, Pastene NE, Fernandez RP, Cordova MP. Therapeutic potential of Cannabis sativa. Revista medica de Chile. 2017;145(3):360-7.
  52. Slawek D, Meenrajan SR, Alois MR, Comstock Barker P, Estores IM, Cook R. Medical Cannabis for the Primary Care Physician. Journal of Primary Care & Community Health. 2019;10:1-7.
  53. Byars T, Theisen E, Bolton DL, editors. Using Cannabis to treat cancer-related pain2019: Elsevier.
  54. Sawtelle L, Holle LM. Use of Cannabis and cannabinoids in patients with cancer. Annals of Pharmacotherapy. 2021;55(7):870-90.
  55. Fernández‐Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? British journal of clinical pharmacology. 2013;75(2):323-33.
  56. Abrams DI. Integrating Cannabis into clinical cancer care. Current oncology. 2016;23(s1):8-14.
  57. Pellati F, Borgonetti V, Brighenti V, Biagi M, Benvenuti S, Corsi L. Cannabis sativa L. and nonpsychoactive cannabinoids: their chemistry and role against oxidative stress, inflammation, and cancer. BioMed research international. 2018;2018:1-15.
  58. Dariš B, Verboten MT, Knez Ž, Ferk P. Cannabinoids in cancer treatment: Therapeutic potential and legislation. Bosnian journal of basic medical sciences. 2019;19(1):14-23.
  59. Dall'Stella PB, Docema MFL, Maldaun MVC, Feher O, Lancellotti CLP. Case report: clinical outcome and image response of two patients with secondary high-grade glioma treated with chemoradiation, PCV, and cannabidiol. Frontiers in oncology. 2019;8:643.
  60. Turgeman I, Bar-Sela G. Cannabis for cancer–illusion or the tip of an iceberg: A review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology. Expert Opinion on Investigational Drugs. 2019;28(3):285-96.
  61. Oultram JMJ, Pegler JL, Bowser TA, Ney LJ, Eamens AL, Grof CPL. Cannabis sativa: Interdisciplinary strategies and avenues for medical and commercial progression outside of CBD and THC. Biomedicines. 2021;9(3):234.
  62. Leiva B, Carrasco I, Montenegro I, Gaete L, Lemus I, Tchernitchin A, et al. Equol and daidzein decrease migration, invasion and matrix metalloproteinase (MMPs) gene expression in prostate cancer cell lines, DU-145 and PC-3. Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas. 2015;14(3):251-62.
  63. Tomko AM, Whynot EG, Ellis LD, Dupré DJ. Anti-cancer potential of cannabinoids, terpenes, and flavonoids present in Cannabis. Cancers. 2020;12(7):1985.
  64. Hinz B, Ramer R. Anti‐tumour actions of cannabinoids. British journal of pharmacology. 2019;176(10):1384-94.
  65. De Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M, et al. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain. 2019;160(1):136.
  66. Kisková T, Mungenast F, Suváková M, Jäger W, Thalhammer T. Future aspects for cannabinoids in breast cancer therapy. International journal of molecular sciences. 2019;20(7):1673.
  67. Takeda S, Okajima S, Miyoshi H, Yoshida K, Okamoto Y, Okada T, et al. Cannabidiolic acid, a major cannabinoid in fiber-type Cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. Toxicology letters. 2012;214(3):314-9.
  68. Sharafi G, He H, Nikfarjam M. Potential use of cannabinoids for the treatment of pancreatic cancer. Journal of pancreatic cancer. 2019;5(1):1-7.
  69. Singh Y, Bali C. Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation. Case reports in oncology. 2013;6(3):585-92.
  70. Pritchard ER, Dayer L, Belz J, Forseth B, Harrington SE, Painter JT. Effect of cannabis on opioid use in patients with cancer receiving palliative care. Journal of the American Pharmacists Association. 2020;60(1):244-7.
  71. Karim S, Cheung WY, Bu J, Jess E, Kerba M. Medical Cannabis authorization in patients with cancer in the prelegalization era: A population-based study. Journal of pain and symptom management. 2020;59(6):1223-31.
  72. Zolotov Y, Eshet L, Morag O. Preliminary assessment of medical Cannabis consumption by cancer survivors. Complementary Therapies in Medicine. 2021;56:1-5.
  73. Blake A, Wan BA, Malek L, DeAngelis C, Diaz P, Lao N, et al. A selective review of medical Cannabis in cancer pain management. Annals Palliative Medicine 2017;6(Suppl 2):S215-S22.
  74. MacCallum CA, Russo EB. Practical considerations in medical Cannabis administration and dosing. European journal of internal medicine. 2018;49:12-9.
  75. Bar-Sela G, Zalman D, Semenysty V, Ballan E. The effects of dosage-controlled Cannabis capsules on cancer-related cachexia and anorexia syndrome in advanced cancer patients: pilot study. Integrative cancer therapies. 2019;18:1-8.
  76. Borges RS, Da Silva ABF. Chaper e12-Cannabidiol as an antioxidant. Handbook of Cannabis and Related Pathologies: Elsevier; 2017. p. e122-e30.
  77. Hu Y, Zeng Z, Wang B, Guo S. Trans-caryophyllene inhibits amyloid β (Aβ) oligomer-induced neuroinflammation in BV-2 microglial cells. International immunopharmacology. 2017;51:91-8.
  78. Raja A, Ahmadi S, de Costa F, Li N, Kerman K. Attenuation of oxidative stress by cannabinoids and Cannabis extracts in differentiated neuronal cells. Pharmaceuticals. 2020;13(11):328.
  79. Khaksar S, Bigdeli MR. Anti-excitotoxic effects of cannabidiol are partly mediated by enhancement of NCX2 and NCX3 expression in animal model of cerebral ischemia. European journal of pharmacology. 2017;794:270-9.
  80. Libzon S, Schleider LB-L, Saban N, Levit L, Tamari Y, Linder I, et al. Medical cannabis for pediatric moderate to severe complex motor disorders. Journal of child neurology. 2018;33(9):565-71.
  81. dos‐Santos‐Pereira M, Guimaraes FS, Del‐Bel E, Raisman‐Vozari R, Michel PP. Cannabidiol prevents LPS‐induced microglial inflammation by inhibiting ROS/NF‐κB‐dependent signaling and glucose consumption. Glia. 2020;68(3):561-73.
  82. Thapa D, Cairns EA, Szczesniak A-M, Toguri JT, Caldwell MD, Kelly ME. The cannabinoids Δ8THC, CBD, and HU-308 act via distinct receptors to reduce corneal pain and inflammation. Cannabis and cannabinoid research. 2018;3(1):11-20.
  83. Pamplona FA, da Silva LR, Coan AC. Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Front Neurol. 2018;9:759-.
  84. Gonçalves ECD, Baldasso GM, Bicca MA, Paes RS, Capasso R, Dutra RC. Terpenoids, Cannabimimetic Ligands, beyond the Cannabis Plant. Molecules. 2020;25(7):1567.
  85. Hanuš LO, Hod Y. Terpenes/Terpenoids in Cannabis: Are They Important? Medical Cannabis and Cannabinoids. 2020;3(1):25-60.
  86. Gallily R, Yekhtin Z, Hanuš LO. The anti-inflammatory properties of terpenoids from cannabis. Cannabis and Cannabinoid Research. 2018;3(1):282-90.
  87. Namdar D, Voet H, Ajjampura V, Nadarajan S, Mayzlish-Gati E, Mazuz M, et al. Terpenoids and Phytocannabinoids Co-Produced in Cannabis Sativa Strains Show Specific Interaction for Cell Cytotoxic Activity. Molecules. 2019;24(17):3031.
  88. Lewis MA, Russo EB, Smith KM. Pharmacological foundations of Cannabis chemovars. Planta medica. 2018;84(04):225-33.
  89. Santiago M, Sachdev S, Arnold JC, McGregor IS, Connor M. Absence of entourage: terpenoids commonly found in cannabis sativa do not modulate the functional activity of Δ9-THC at human CB1 and CB2 receptors. Cannabis and cannabinoid research. 2019;4(3):165-76.
  90. Finlay DB, Sircombe KJ, Nimick M, Jones C, Glass M. Terpenoids from Cannabis do not mediate an entourage effect by acting at cannabinoid receptors. Frontiers in pharmacology. 2020;11:359.
  91. Häuser W, Finn DP, Kalso E, Krcevski‐Skvarc N, Kress HG, Morlion B, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis‐based medicines and medical cannabis for chronic pain management. European Journal of Pain. 2018;22(9):1547-64.
  92. Busardò FP, Pérez-Acevedo AP, Pacifici R, Mannocchi G, Gottardi M, Papaseit E, et al. Disposition of phytocannabinoids, their acidic precursors and their metabolites in biological matrices of healthy individuals treated with vaporized medical Cannabis. Pharmaceuticals. 2021;14(1):59.
  93. Kleckner AS, Kleckner IR, Kamen CS, Tejani MA, Janelsins MC, Morrow GR, et al. Opportunities for Cannabis in supportive care in cancer. Therapeutic advances in medical oncology. 2019;11:1-29.
  94. Meng H, Dai T, Hanlon JG, Downar J, Alibhai SMH, Clarke H. Cannabis and cannabinoids in cancer pain management. Current Opinion in Supportive and Palliative Care. 2020;14(2):87-93.
  95. Ewing LE, Skinner CM, Quick CM, Kennon-McGill S, McGill MR, Walker LA, et al. Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model. Molecules. 2019;24(9):1694.
  96. Dziwenka M, Coppock R, Alexander M, Palumbo E, Ramirez C, Lermer S. Safety assessment of a hemp extract using genotoxicity and oral repeat-dose toxicity studies in sprague-dawley rats. Toxicology reports. 2020;7:376-85.
  97. Harpaz D, Veltman B, Sadeh Y, Marks RS, Bernstein N, Eltzov E. The effect of Cannabis toxicity on a model microbiome bacterium epitomized by a panel of bioluminescent E. coli. Chemosphere. 2021;263:1-10.
  98. Semana. Cannabis medicinal, una necesidad en la ciencia. Semana. 2020.
  99. Suárez M. Khiron firma acuerdo con Locatel para distribuir cannabis medicinal en Colombia. WRadio. 2020.

Descargas

Los datos de descargas todavía no están disponibles.